Short answer: In the head-to-head ACHIEVE-3 trial, the oral GLP-1 pill orforglipron (now sold as Foundayo) beat the oral semaglutide pill on both blood sugar and weight loss in adults with type 2 diabetes. But it came with more gastrointestinal side effects, roughly double the dropout rate, and it does not yet carry the cardiovascular risk-reduction indication that oral semaglutide has. So “better on paper” is not the same as “better for every patient.”
Watch the full breakdown
What is orforglipron (Foundayo)?
Orforglipron is a once-daily oral GLP-1 receptor agonist. Unlike the oral semaglutide pill, which has to be taken on an empty stomach with a small amount of water followed by a 30-minute wait, orforglipron is a small-molecule drug that can be taken any time of day with no food or water restrictions. The FDA approved it under the brand name Foundayo in April 2026 for adults with obesity, or overweight with a weight-related condition. It is available through telehealth and retail pharmacies now.
Important detail most coverage blurs: the ACHIEVE-3 trial studied orforglipron in people with type 2 diabetes, while the current FDA approval is for obesity. The trial data below is diabetes data.
What did the ACHIEVE-3 trial find?
ACHIEVE-3 was the first Phase 3 trial to put two oral GLP-1 pills head to head. It enrolled 1,698 adults with type 2 diabetes inadequately controlled on metformin and randomized them across four arms for 52 weeks: orforglipron 12 mg or 36 mg, versus oral semaglutide 7 mg or 14 mg (Rosenstock J, et al. Lancet. 2026; PMID 41765029).
On the primary endpoint, blood sugar, orforglipron at the 36 mg dose lowered HbA1c by roughly 2 percentage points from a baseline of 8.3%, compared with about 1.4 points for oral semaglutide 14 mg. Both orforglipron doses were not just non-inferior but statistically superior to both semaglutide doses.
Is orforglipron better than the Ozempic pill for weight loss?
For weight, yes, on average and in this population. At the top dose, orforglipron patients lost about 9.2% of body weight, close to 20 pounds, versus about 5.3%, roughly 11 pounds, on oral semaglutide 14 mg. At the lower doses, orforglipron 12 mg produced about 6.7% weight loss versus 3.7% on oral semaglutide 7 mg (Rosenstock J, et al. Lancet. 2026; PMID 41765029).
That is a meaningful gap. But weight loss is only one side of the ledger.
What are the side effects of orforglipron?
This is the part the headlines skip. Gastrointestinal side effects, mainly nausea, vomiting, and diarrhea, occurred in close to 60% of orforglipron patients, compared with roughly 37% to 45% of oral semaglutide patients. More importantly, the discontinuation rate tells the real story: about 8.7% to 9.7% of orforglipron patients stopped because of side effects, versus roughly 4.5% to 4.9% on oral semaglutide. That is about double. Orforglipron was also associated with a slightly larger increase in heart rate (Rosenstock J, et al. Lancet. 2026; PMID 41765029).
The pattern is a familiar one in this drug class: the agent that delivers the bigger benefit is often the one more patients struggle to tolerate long enough to get it.
The cardiovascular caveat nobody leads with
Here is the clinical point that changes the decision for a lot of people. Oral semaglutide currently holds the only approved indication among oral GLP-1 pills for reducing cardiovascular risk. Orforglipron does not have that yet. Beating another drug on HbA1c and pounds is not the same as beating it on the outcomes that keep people out of the hospital. For a patient whose largest risk sits with their heart, the pill that “lost” on weight may still be the better choice.
Who should consider which?
This is an individualized decision, and it belongs with your own clinician, not a comment section. In general terms, the trial suggests three practical takeaways. First, if orforglipron is on the table, titration matters even more; the study forced dose escalation, and in real practice starting low and going slow can dramatically improve tolerability. Second, the right pill depends on what you are actually treating, bigger weight and glucose reductions point one direction, established cardiovascular protection points another. Third, remember the indication gap between the trial population (diabetes) and the current approval (obesity).
Frequently asked questions
Is orforglipron the same as Ozempic?
No. Orforglipron (Foundayo) is a different, small-molecule oral GLP-1 drug made by Eli Lilly. Ozempic is injectable semaglutide from Novo Nordisk; the oral semaglutide pill is a separate product. ACHIEVE-3 compared orforglipron against the oral semaglutide pill, not the injection.
Did orforglipron beat oral semaglutide?
On blood sugar and weight loss in adults with type 2 diabetes, yes, orforglipron was statistically superior at the doses tested. It also had more gastrointestinal side effects and a higher discontinuation rate.
Is orforglipron FDA approved?
Yes. It was approved as Foundayo in April 2026 for obesity, or overweight with a weight-related condition. The diabetes data discussed here comes from clinical trials.
Why might a doctor still prefer the oral semaglutide pill?
Because oral semaglutide currently carries an approved cardiovascular risk-reduction indication that orforglipron does not, and because it may be better tolerated for some patients.
Considering a GLP-1 and want a clinician who will walk you through the tradeoffs? Book a consult with Moxie Wellness.
Medical disclaimer: This article is for educational purposes only and is not medical advice. It does not create a provider-patient relationship. Talk to your own clinician before making any treatment decision.
This article was produced with AI-assisted tools. All clinical claims are sourced to the primary literature cited below.
Sources
- Rosenstock J, et al. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet. 2026. doi:10.1016/S0140-6736(26)00202-3. PMID 41765029.
- Frías JP / Rosenstock J, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1). N Engl J Med. 2025;393(11). doi:10.1056/NEJMoa2505669.
- U.S. FDA approval of Foundayo (orforglipron), Eli Lilly and Company, April 1, 2026.